Introduction
Human airway smooth muscle cells (HASMC) are key determinants of asthma owing to their ability to contract in response to inflammatory cell products (1) . Due to their intrinsic phenotype plasticity, airway myocytes also exhibit a capacity for multifunctional behavior and are actively involved in local inflammation and fibrosis (15) . Emerging evidence suggests that HASMC can also directly contribute to the pathogenesis of asthma by altering the interstitial extracellular matrix, expressing cell adhesion and costimulatory molecules, as well as secreting multiple pro-inflammatory cytokines and chemokines (19, 26) . These responses can perpetuate airway inflammation and act on the hyperplastic and hypertrophic growth of HASMC contributing to airway hyperresponsiveness (AHR) and development of airway remodeling (39).
Interleukin (IL)-1 is a pro-inflammatory mediator released by activated airway macrophages and epithelium and is found in elevated levels in the bronchoalveolar lavage (BAL) fluid of asthmatic, chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS) patients (4, 7, 8) . In vivo and in vitro assays have demonstrated that IL-1 can alter airway function by inducing cellular infiltrate, mucus hyperplasia, airway wall thickening, fibrosis and enlargement of distal airspaces (21, 25) .
Effector mechanisms include secretion of IL-8 (CXCL-8) which has been demonstrated to modulate HASMC contraction and migration mediating airway responsiveness and remodeling in asthmatic patients (9, 14, 47) . Most importantly, CXCL-8 is recognized to induce the mobilization of neutrophils into the airways, negatively affecting lung and bronchial epithelial function (32).
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Neutrophil chemotactic factors such as CXCL-8, granulocyte macrophage-colony stimulating factor (GM-CSF), leukotriene B4 (LTB 4 ) and complement activation product C5a are increased in BAL fluid from asthmatic individuals (5, 10), however up-stream factors mediating neutrophil recruitment are still elusive. IL-17, a pleiotropic Tlymphocyte cytokine released from a distinctive Th 1 /Th 2 lineage subset (31) is hypothesized to orchestrate the granulocyte influx into the airways via the induction of CXCL-8 (23, 27) . In humans, elevated IL-17 levels can be detected in sera, sputum and BAL fluid from asthmatic patients and have been shown to correlate with BAL neutrophilia, myeloperoxidase levels and AHR (3, 11, 18, 28, 33) . Recently, the effect of IL-17 on tumor necrosis factor-(TNF-) stimulated lung structural cells has gained attention for its synergistic induction of neutrophilic mobilizing chemokines (22, 24, 41 ).
Increases in CXCL-8 and IL-6 levels in vitro have equally been reported for these cytokines in primary HASMC (16, 17) . However, the modulating effect of IL-17 on IL-1 mediated CXCL-8 induction in HASMC has not been investigated.
We previously established that IL-17 induces CXCL-8 expression in primary HASMC (35) . In this study, we demonstrate a role for IL-17 in synergizing IL-1 induced CXCL-8 release from primary HASMC. The synergistic effect of combining IL-17 with IL-1 is regulated at the transcriptional level and is dependent on the cooperative function of AP-1 and NF-B cis-acting elements. Erk-1/2, p38 mitogen-activated protein kinases (MAPKs) and the phosphatidylinositol 3-kinase (PI3-K) pathway mediate the upstream signal transduction of CXCL-8 promoter activity. Collectively, our observations indicate IL-17 may potentiate the functional recruitment of neutrophils by IL-1 via the induction of CXCL-8 and potentially exacerbate airway inflammation.
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Materials and Methods
Reagents and antibodies
Recombinant human IL-17 and IL-1 were purchased from R&D (Minneapolis, MN).
Dulbecco's Modified Eagle Medium (DMEM), Ham's F-12 media, antibiotics (penicillin, streptomycin), deoxyribonucleotide triphosphate (dNTP), superscript reverse transcriptase and Taq polymerase were purchased from (GibcoBRL, Grand Island, NY). 
Preparation of bronchial HASMC
Bronchial HASMC were obtained from macroscopically healthy segments of the main bronchus after lung resection from surgical patients in accordance with procedures approved by the Human Research Ethics Board of the University of Manitoba. Primary HASMC cultures were established and performed as previously described (35) . HASMC were grown at 37°C with 5% CO 2 in DMEM with 10% FBS and antibiotics (100U/ml penicillin and 100µg/ml streptomycin). In all experiments, cells were used at passages 2 to 5.
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Cell stimulation and ELISA assay Confluent HASMC were growth arrested by FBS deprivation for 48h in Ham's F-12 media containing 5µg/ml of human recombinant insulin, 5µg/ml of human transferrin, 5ng/ml of selenium and antibiotics (100U/ml penicillin and 100µg/ml streptomycin). Cells were then stimulated in fresh FBS-free media with human recombinant IL-17 (0.1, 1, 10 and 100ng/ml), IL-1 (0.1, 1, 10 and 100ng/ml), in combination or vehicle (PBS).
Supernatants were collected at different time points (24 and 48h), centrifuged for 7min at 4ºC to remove cellular debris, and stored at -80°C prior to ELISA. To test the effect of mRNA synthesis inhibitor actinomycin-D (Act-D) on CXCL-8 mRNA or protein release, 5µg/ml was added to serum-deprived HASMC 30min before stimulation with IL-17 (1ng/ml), IL-1 (1ng/ml) or both (40) . Supernatants were recovered at 24 and 48h and processed as described above. Immuno-reactive CXCL-8 was quantified by ELISA using matched antibodies from Pierce Endogen (Biosource International, Missisauga, Ontario) according to basic laboratory protocols. The sensitivity limit of CXCL-8 was 10pg/ml.
Real-time RT-PCR analysis
Confluent HASMC were growth arrested by FBS deprivation and were stimulated in fresh FBS-free media containing IL-17 (1ng/ml), IL-1 (1ng/ml), both or vehicle (PBS) for 6h. Cells were then harvested and RNA was purified using the guanidinium isothiocyanate method (6) . Relative levels of CXCL-8 mRNA were analyzed by quantitative real-time RT-PCR analysis using the Light-Cycler (Roche) as previously described (35) . Briefly, DNA standards were prepared from PCR using cDNA of cells stimulated with IL-1 (1ng/ml). The amount of extracted DNA was quantified by spectrophotometry and expressed as copy numbers and serial dilutions were used to generate the standard curve. Product specificity was determined by melting curve analysis and by visualization of the PCR products on agarose gel. Calculation of the relative amount of each cDNA species was performed as previously described (13). The amplification of target genes in stimulated cells was calculated by first normalizing to the amplification of GAPDH and then expressing the normalized values as fold increase over the value obtained with unstimulated control cells.
CXCL-8 mRNA stability
Growth arrested HASMC were stimulated with IL-1 (1ng) or in combination with IL-17 
CXCL-8 promoter luciferase reporter constructs and cell transfection
CXCL-8 promoter was amplified from human cell genomic DNA using PCR with specific primers as previously described (35) . Briefly, HASMC (4x10 4 ) were seeded into 24 well plates in complete media (DMEM/10%FBS). At 70% confluency, transfection 
Results
IL-17 enhances IL-1 mediated CXCL-8 protein release from HASMC
We 
IL-17 enhances IL-1 mediated CXCL-8 promoter activity
To investigate whether IL-17 modulates CXCL-8 promoter activity, HASMC were transiently transfected with the proximal CXCL-8 promoter fused to the luciferase reporter gene followed by stimulation with suboptimal concentrations (0.1 and 1ng/ml) of IL-17, IL-1 or in combination. IL-17 alone induced a 1.8 and 4.2 fold increase at 0.1 and 1ng/ml respectively, compared to vehicle (Fig. 3) . Similarly, IL-1 at 0.1 and 1ng/ml led to a 10.0 and 23.7 fold increase in reporter gene activity compared to vehicle. A significant synergistic effect on reporter gene activity was observed at 1ng/ml of IL-17 in combination with IL-1 (1.6 fold increase compared to IL-1 alone, Fig. 3B ). The combination of both cytokines at different concentrations did not yield better synergistic effects than those shown at 1ng/ml (data not shown). Taken together, these results demonstrate the synergy observed between IL-17 and IL-1 is mediated at the CXCL-8 promoter level.
IL-17 synergizes with IL-1 and requires intact AP-1 and NF-B response elements
To ascertain which transcription factor binding sites were functionally important for the 
IL-17 enhances IL-1 mediated CXCL-8 promoter activity through p38, Erk-1/2 MAPK and the PI3-K pathway
To further define the molecular mechanism by which IL-17 and IL-1 cooperate, we used selective pharmacological inhibitors of p38 (SB203580), MEK-1/2 (U0126) and PI3-K Fig. 5A ). In contrast, inhibition of PI3-K with wortmannin had no effect on IL-17 induced CXCL-8 promoter activity in HASMC (Fig. 5A) . Pre-treatment with SB 203580, U0126 or wortmannin significantly decreased IL-1 induced CXCL-8
promoter activity by 28.8±14.8%, 77.8±2.9% and 51.8±11.4% respectively (Fig. 5B) . 
